Cartesian Financial Statements From 2010 to 2025

RNAC Stock   6.68  0.08  1.18%   
Cartesian Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Cartesian Therapeutics' valuation are provided below:
Gross Profit
-51.8 M
Market Capitalization
173.7 M
Enterprise Value Revenue
41.2497
Revenue
1.1 M
Earnings Share
(1.33)
We have found one hundred twenty available fundamental signals for Cartesian Therapeutics, which can be analyzed and compared to other ratios and to its rivals. Investors should ensure to validate all of Cartesian Therapeutics' prevailing performance against the performance from 2010 to 2025 to make sure the company is sustainable down the road. The current year's Market Cap is expected to grow to about 133.5 M, whereas Enterprise Value is forecasted to decline to about 39 M.

Cartesian Therapeutics Total Revenue

30.23 Million

Check Cartesian Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Cartesian Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.4 M, Interest Expense of 0.0 or Selling General Administrative of 21.7 M, as well as many indicators such as Price To Sales Ratio of 11.33, Dividend Yield of 0.0 or Days Sales Outstanding of 7.77. Cartesian financial statements analysis is a perfect complement when working with Cartesian Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with Cartesian Stock
Check out the analysis of Cartesian Therapeutics Correlation against competitors.
For information on how to trade Cartesian Stock refer to our How to Trade Cartesian Stock guide.

Cartesian Therapeutics Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets456.8 M435 M136 M
Slightly volatile
Short and Long Term Debt Total23 M14 M17.7 M
Slightly volatile
Other Current Liabilities15.5 M19.8 M11.4 M
Slightly volatile
Total Current Liabilities38.1 M23 M28.5 M
Slightly volatile
Other Liabilities28.8 M42.4 M22.6 M
Slightly volatile
Property Plant And Equipment Net7.8 M15.4 M5.9 M
Slightly volatile
Current Deferred Revenue2.5 M2.7 M9.7 M
Pretty Stable
Accounts Payable273.6 K288 K982.3 K
Very volatile
Cash223.2 M212.6 M77.8 M
Slightly volatile
Non Current Assets Total229.3 M218.4 M46.2 M
Slightly volatile
Other Assets2.3 M1.5 M1.8 M
Pretty Stable
Cash And Short Term Investments223.2 M212.6 M83.9 M
Slightly volatile
Net Receivables828.4 K872 K3.3 M
Slightly volatile
Common Stock Shares Outstanding24.9 M23.7 M5.1 M
Slightly volatile
Liabilities And Stockholders Equity456.8 M435 M136 M
Slightly volatile
Non Current Liabilities Total439.8 M418.8 M158.5 M
Slightly volatile
Other Current AssetsM3.1 M3.2 M
Slightly volatile
Other Stockholder Equity724.4 M689.9 M253 M
Slightly volatile
Total Liabilities463.9 M441.8 M186.1 M
Slightly volatile
Deferred Long Term Liabilities404.2 K425.5 K2.6 M
Pretty Stable
Property Plant And Equipment Gross9.1 M17.8 M6.8 M
Slightly volatile
Total Current Assets113.4 M216.6 M82.7 M
Slightly volatile
Common Stock2.9 KK5.1 K
Slightly volatile
Property Plant Equipment2.2 M3.2 M2.1 M
Slightly volatile
Common Stock Total Equity18.1 K17.2 K6.9 K
Slightly volatile
Capital Surpluse385.7 M567.3 M323 M
Slightly volatile
Cash And Equivalents96.8 M122.4 M80.8 M
Slightly volatile
Net Working Capital203.3 M193.7 M90.9 M
Slightly volatile
Capital Stock2.9 KKK
Slightly volatile
Capital Lease Obligations10.5 M14 M4.4 M
Slightly volatile

Cartesian Therapeutics Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization1.4 M1.2 M1.2 M
Slightly volatile
Selling General Administrative21.7 M30.1 M16.9 M
Slightly volatile
Total Revenue30.2 M38.9 M21.5 M
Slightly volatile
Gross Profit30 M38.9 M21.4 M
Slightly volatile
Other Operating Expenses73.6 M82.8 M55.2 M
Slightly volatile
Research Development51.1 M45.1 M37.7 M
Slightly volatile
Cost Of Revenue1.3 M1.4 M16.5 M
Slightly volatile
Total Operating Expenses73.1 M82.8 M54.8 M
Slightly volatile
Interest Income7.8 M7.4 M1.8 M
Slightly volatile
Reconciled Depreciation1.2 M1.2 M969.3 K
Slightly volatile

Cartesian Therapeutics Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation7.3 M6.6 M5.3 M
Slightly volatile
Begin Period Cash Flow75.7 M78.3 M54 M
Slightly volatile
Depreciation1.2 M1.2 MM
Slightly volatile
Other Non Cash Items54.1 M51.5 M19.4 M
Slightly volatile
Capital Expenditures9.5 M9.1 M1.7 M
Slightly volatile
End Period Cash Flow225 M214.3 M78.3 M
Slightly volatile
Dividends Paid157.3 K165.6 K3.7 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio11.3311.92375.8143
Pretty Stable
Days Sales Outstanding7.778.179393.5109
Very volatile
Stock Based Compensation To Revenue0.260.16910.3413
Pretty Stable
Capex To Depreciation8.37.90011.5193
Slightly volatile
EV To Sales6.486.818656.2628
Pretty Stable
Payables Turnover0.540.575.3377
Slightly volatile
Sales General And Administrative To Revenue1.20.77421.4946
Slightly volatile
Research And Ddevelopement To Revenue1.11.159119.4944
Very volatile
Capex To Revenue0.220.23370.3563
Very volatile
Cash Per Share7.88.207367.4456
Pretty Stable
Days Payables Outstanding700666178
Slightly volatile
Intangibles To Total Assets0.610.45690.6368
Slightly volatile
Current Ratio9.99.42844.0876
Slightly volatile
Receivables Turnover46.8644.62511.8711
Slightly volatile
Capex Per Share0.330.3510.8025
Slightly volatile
Revenue Per Share1.431.502110.1479
Very volatile
Interest Debt Per Share0.510.539820.2602
Slightly volatile
Debt To Assets0.03050.03210.2325
Slightly volatile
Graham Number54.3861.1766.6917
Slightly volatile
Operating Cycle7.778.179393.5109
Very volatile
Days Of Payables Outstanding700666178
Slightly volatile
Ebt Per Ebit1.181.75721.2952
Slightly volatile
Quick Ratio9.99.42844.0876
Slightly volatile
Net Income Per E B T1.541.00372.2619
Slightly volatile
Cash Ratio9.729.25363.4649
Slightly volatile
Days Of Sales Outstanding7.778.179393.5109
Very volatile
Free Cash Flow Operating Cash Flow Ratio0.841.38411.0289
Pretty Stable
Fixed Asset Turnover2.482.51912.6723
Slightly volatile
Debt Ratio0.03050.03210.2325
Slightly volatile
Price Sales Ratio11.3311.92375.8143
Pretty Stable
Asset Turnover0.140.08950.1637
Pretty Stable
Gross Profit Margin1.061.080.9901
Slightly volatile

Cartesian Therapeutics Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap133.5 M91.5 M157.3 M
Very volatile
Enterprise Value39 M41 M111 M
Slightly volatile

Cartesian Fundamental Market Drivers

Forward Price Earnings25.4453
Cash And Short Term Investments212.6 M

Cartesian Upcoming Events

7th of March 2024
Upcoming Quarterly Report
View
2nd of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
7th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Cartesian Therapeutics Financial Statements

Cartesian Therapeutics stakeholders use historical fundamental indicators, such as Cartesian Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Although Cartesian Therapeutics investors may analyze each financial statement separately, they are all interrelated. For example, changes in Cartesian Therapeutics' assets and liabilities are reflected in the revenues and expenses on Cartesian Therapeutics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Cartesian Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue2.7 M2.5 M
Total Revenue38.9 M30.2 M
Cost Of Revenue1.4 M1.3 M
Stock Based Compensation To Revenue 0.17  0.26 
Sales General And Administrative To Revenue 0.77  1.20 
Research And Ddevelopement To Revenue 1.16  1.10 
Capex To Revenue 0.23  0.22 
Revenue Per Share 1.50  1.43 
Ebit Per Revenue(1.13)(1.18)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Cartesian Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Cartesian Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Cartesian Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Cartesian Therapeutics Stock:
Check out the analysis of Cartesian Therapeutics Correlation against competitors.
For information on how to trade Cartesian Stock refer to our How to Trade Cartesian Stock guide.
You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cartesian Therapeutics. If investors know Cartesian will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cartesian Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.07)
Earnings Share
(1.33)
Revenue Per Share
0.042
Quarterly Revenue Growth
0.168
Return On Assets
(0.13)
The market value of Cartesian Therapeutics is measured differently than its book value, which is the value of Cartesian that is recorded on the company's balance sheet. Investors also form their own opinion of Cartesian Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Cartesian Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cartesian Therapeutics' market value can be influenced by many factors that don't directly affect Cartesian Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cartesian Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cartesian Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cartesian Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.